ACTIVE
- NIH R01 HL139963 (Ishikawa) 12/15/2017 – 11/30/2022 Percutaneous Left Ventricular Unloading for Cardiogenic Shock: Beyond Acute Hemodynamic Support
- Abiomed Inc. (Ishikawa) 03/01/2016 – 12/31/2025 Improving the gene transduction efficacy of intracoronary delivery using an Impella Role (PI)
- Cardiac RSK3 inhibitors (Ishikawa) 9/30/2021-9/29/2022 AAV-RBD gene therapy in a pig model of myocardial infarction
- NIH R01HL148786 (Sahoo) 07/01/2019 – 06/30/2024 AAV-Exosomes: Escaping Neutralizing Antibody and Enhancing Delivery Role (Co-I)
- NIH NHLBI GTRP RSA 2035 (Ishikawa) Preclinical Vector Production “Improving Cardiac AAV Gene Transduction Using Intracoronary Delivery”
- T32 Research Fellowship (Marvopoulos) 06/28/2021 – 06/27/2024
- ACURE Research Fellowship Grant (Sakata) 07/01/2021 – 06/30/2022
-
Completed
- NIH/NHLBI 1R01HL130423-01 (Ishikawa/Kovacic) 01/25/2016 – 12/31/2021 Toward Therapeutic Manipulation of Endothelial to Mesenchymal Transition. Role (Co-PI)
- NIH/NHLBI 1R01HL135093 (Fish/Kovacic) 12/01/2016 – 11/30/2021 Therapeutic Mechanisms of Cardiac Progenitors in Ischemic Cardiomyopathy Role (Co-I)
- AHA-SDG 17SDG33410873 (Ishikawa) 01/01/2017 – 12/31/2019 Mechanistic and Therapeutic Roles of miRNAs in Left Ventricular Remodeling and Heart Failure Role (PI)
- NIH R01HL131404 (Hajjar/Weber) 07/01/2016 – 06/30/2020 Anti-AAV Antibodies as an Obstacle to Cardiac AAV Gene Therapy Role (Co-I)
- Cardiac RSK3 Inhibitors, LLC (Fish) 02/06/2019 – 02/05/2020 Gene Therapy for Cardiac Remodeling
- T32 Research Fellowship (Mazurek) 09/22/2020 – 09/21/2021